Trial Profile
Phase 1b Study of Venetoclax in Combination With Intensive Induction and Consolidation Chemotherapy in Treatment Naïve Subjects With Acute Myelogenous Leukemia
Status:
Recruiting
Phase of Trial:
Phase I
Latest Information Update: 15 Feb 2024
Price :
$35
*
At a glance
- Drugs Venetoclax (Primary) ; Cytarabine; Daunorubicin
- Indications Acute myeloid leukaemia
- Focus Adverse reactions
- 08 Jan 2024 Planned primary completion date changed from 1 Jan 2024 to 1 Jul 2024.
- 06 Mar 2023 Planned primary completion date changed from 1 Jun 2023 to 1 Jan 2024.
- 06 Mar 2023 Status changed from suspended to recruiting.